Table 1 Characteristics of cases and controls   Cases (n = 6,763), % Controls (n = 26,341), % Crude OR [95% CI] Gender   Male 1,834 (27.1) 7,203 (27.3)     Female

4,929 (72.9) 19,138 (72.7)   Age (years)   18–49 452 (6.7) 1,808 (6.9)     50–69 1,061 (15.7) 4,239 (16.1)     ≥70 5,250 (77.6) 20,294 (77.0)   Hospitalisation before the index date   Cardiovascular disease 359 (5.3) 1,289 (4.9) 1.10 [0.98–1.25]   Cerebrovascular disease 296 (4.4) 565 (2.1) 2.12 [1.84–2.45]   Parkinson’s disease 23 (0.3) 41 (0.2) 2.24 [1.34–3.75]   Mental disorders 24 (0.4) 36 (0.1) 2.54 [1.51–4.27] Drug use 6 months before the index date   Benzodiazepinesa 967 (14.3) 2,751 (10.4) 1.44 [1.33–1.56]   Antidepressants 643 (9.5) 1,343 (5.1) 2.00 [1.81–2.21]   Antipsychotics 412 (6.2) 921 (3.5) 1.79 [1.58–2.02] Current drug use at index date   Amantadine CP-690550 cost 30 (0.4) 42 (0.2) 2.78 [1.74–4.44]   Selegeline 56 (0.8) 51 (0.2) 4.37 [2.98–6.41]   Anticholinergics 43 (0.6) 67 (0.3) 2.52 [1.72–3.70]   Cathechol-O-methyltransferase inhibitors 1 (0.0) 5 (0.0) 0.80 [0.09–6.85] a3 months before the index date As shown in Table 2, the risk of hip/femur fractures was nearly doubled among current users of dopaminergic drugs compared to no use (ORadj = 1.76, 95% CI = 1.39–2.22). Further stratified analyses suggested that the risk of hip/femur fracture for current users of dopaminergic drugs were not ICG-001 supplier different for men and women. Table 2 Use of dopaminergic drugs and risk of hip/femur fracture   Cases

(n = 6,763), % Controls (n = 26,341), % Crude OR [95% CI] ORadj a [95% CI] Never use 6,578 (97.3) 25,996 (98.7) Reference Reference Ever use 185 (2.7) 345 (1.3) 2.13 [1.77−2.56] 1.50 [1.22−1.84] many Among ever users of a dopaminergic drug          Past use (>182 days before the index date) 20 (0.3) 81 (0.3) 0.98 [0.59−1.60] 0.91 [0.55−1.51]  Recent use (31−182 days before the index date) 9 (0.1) 27 (0.1) 1.28 [0.60−2.73] 1.01 [0.47−2.20]  Current use (1−30 days before the index date) 156 (2.3) 237 (0.9) 2.62 [2.13−3.22] 1.76 [1.39−2.22]b   By gender            Male 45 (0.7) 64 (0.2) 2.83 [1.92−4.17] 1.84 [1.21−2.81]    Female 111 (1.6) 173 (0.7) 2.54 [1.99−3.24] 1.73 [1.32−2.26]   By age category (years)            18−69 13 (0.2) 20 (0.1) 2.60 [1.29−5.23] 1.54 [0.73−3.24]    ≥70 143 (2.1) 217 (0.8) 2.62 [2.11−3.25] 1.78 [1.39−2.27] aAdjusted for: (a) a history in the past year of hospitalisation for Parkinson’s disease; (b) use in the past 6 months of antidepressants; and (c) current use of amantadine, selegeline and anticholinergics b p = 0.